EMA has approved the subcutaneous version of CT-P13 an infliximab biosimilar based on this trial by Rene Westhovens. Equal efficacy of IV and SC CT-P13 with great maintenance on SC form. Interestingly high trough levels with SC CT-P13. #ACR19 @RheumNow Abst 807 https://t.co/hfrtJRMPdt